News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Agennix AG Announces U.S. Class Action Lawsuit Against Predecessor GPC Biotech AG (GPCG.DE) Fully Closed

2/10/2010 10:51:50 AM

MARTINSRIED, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - February 10, 2010) - Agennix AG (FRANKFURT: AGX) today announced that the class action lawsuit brought against its predecessor, GPC Biotech AG, in the United States District Court for the Southern District of New York, is now fully closed.

In March 2009, the Court issued an order dismissing the consolidated class action complaint against GPC Biotech in the action that was commenced in July 2007. Pursuant to that order, the plaintiffs were given the opportunity to file a motion seeking permission of the Court to file an amended consolidated class action complaint. The plaintiffs subsequently filed this motion with the Court and the Company opposed the request. On December 29, 2009 the Court issued a decision denying the plaintiff's request to file an amended complaint and ordered that judgment be entered dismissing the complaint in accordance with the Court's decision of March 12, 2009, with prejudice. The period to file an appeal to that decision has now expired and the case is fully closed.

About Agennix

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company's most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Agennix also has recently reported positive results from a Phase 2 trial evaluating talactoferrin in severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel

Hilda Juhasz

Additional investor contact for Europe:
Trout International LLC
Lauren Williams
Vice President
Phone: +44 207 936 9325

Read at

comments powered by Disqus